Hemas Holdings Ltd. · CSELK:HHL.N0000
Hemas — Q3 FY23/24 Earnings Presentation
30 slides from Hemas's earnings presentation, 2024
Slide 1: Hemas Holdings PLC Investor Presentation - Q3 FY23/24
Hemas Holdings PLC Investor Presentation- Q3 FY23/24
Slide 2: Who we are
Who we are Established in 1948, with a purpose of empowering families to live a better tomorrow, Hemas Holdings is one of Sri Lanka’s leading conglomerates listed in the Colombo Stock exchange with focused interest in Consumer and Healthcare. Key Milestones “Established Hemas Drugs Pvt 1948 Ltd” “IP
Slide 3: Implications of key macro economic parameters on Hemas
Implications of key macro economic parameters on Hemas Inflationary Pressure Stable Exchange Rates Global Commodity prices “Reduced consumer demand across “ Favourable Impact of reduced prices “Positive impact from reduced RM the sectors amidst inflationary of key commodities contributed to costs an
Slide 4: Key strengths
BOM Group CEO Nomination & Governance Committee Human Related Party Resources & Transactions Board Remuneration Review Committee Committee Investment Group Audit Committee Committee Diversified and competent Presence in key defensive segments Leadership Team Healthcare and Consumer Sound Corporate G
Slide 5: Corporate Governance
Corporate Governance BOM Group CEO BOM (Board of Management) Nomination & Consists of the senior leadership team of 11 members - Heads of our 6 businesses and 5 leaders from Corporate Governance Office. BOM is responsible for formulation and implementation of Group strategic plan and ensures that th
Slide 6: Strategic Building Blocks
Strategic Building Blocks Building more from New within the core New business and Efficiencies the core and Adjacencies Internationalisation Accelerate current business Capturing new revenue Explore attractive Efficiency and productivity to efforts to drive higher value streams to further strengthen
Slide 7: New Product Launches during the Quarter
New Product Launches during the Quarter Home and Personal Care Learning Segment ‘Clogard’ Pro Clean Additions to the ‘Velvet Naturals’ Range ‘Diva’ Diriya 1kg Atlas ‘Thematic Cross Category Pack Range’ New ‘Clogard Pancha Shakthi’ toothpaste
Slide 8: Financial Snapshot
Financial Snapshot EBIT By Segment (LKR million) 3,868 280 3,235 2,767 9M contribution to the Group 233 247 2,616 56% 1% 2,095 585 42% 143 3,103 1,477 1,785 42% 9% Revenue 1,517 1,301 65% 1,616 1,271 952 EBIT 658 887 (157) (54) (223) (466) (574) Consumer Healthcare Mobility FY21 Q3 FY22 Q3 FY23 Q3 F
Slide 9: Sector Performance Summary – Q3 FY 2023-24
Sector Performance Summary – Q3 FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 76 1,805 3 47 -431 31,223 1,317 -319 29,770 -411 3,868 3,235 Q3 FY 23 Consumer Mobility Other Healthcare Q3 FY 24 Q3 FY 23 Consumer Mobility Healthcare Other Q3 FY 24
Slide 10: Sector Performance Summary – 9M FY 2023-24
Sector Performance Summary – 9M FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 2,928 -159 5,549 16 -50 90,174 2,026 -415 -623 10,000 8,788 81,730 7,959 8,000 6,000 4,000 2,000 0 9M FY 23 Consumer Healthcare Other Mobility 9M FY 24 9M FY 23 Consumer Healthcare Mobility Other 9M FY 24
Slide 11: Continuing Operation EPS – Q3 FY 2023-24
Continuing Operation EPS – Q3 FY 2023-24 EPS Walk (LKR Per Share) -0.34 0.21 -0.08 0.12 -0.41 1.06 2.29 3.72 3.72 1.15 1.64 1.64 Q3 FY 23 Net Finance Operating NCI Income Tax Q3 FY 24 Q3 FY 23 Consumer Healthcare Mobility Other Q3 FY 24 Cost Profit
Slide 12: Continuing Operation EPS – 9M FY 2023-24
Continuing Operation EPS – 9M FY 2023-24 EPS Walk (LKR Per Share) 0.15 0.07 0.61 7.60 -0.21 3.69 -0.42 1.39 -0.84 7.60 5.38 5.38 9M FY 23 Operating NCI Net Finance Income Tax 9M FY 24 6M FY 23 Consumer Healthcare Mobility Other 6M FY 24 Profit Cost
Slide 13: Capital Employed – Q3 FY 2023-24
Capital Employed – Q3 FY 2023-24 Sector Efficiency Capital Employed, ROCE, and EBIT by Sector 60% Mobility Consumer LKR 751.2 Mn LKR 5,726.0 Mn 50% 40% 42.2% Healthcare 36.0% LKR 3,658.5 Mn 30% Group ROCE :21.2% 20% 16.8% ROCE (%) 10% 0% 0 5 10 15 20 25 30 35 40 -10% -20% Capital Employed (LKR Bn) -
Slide 14: Consumer Brands
Consumer Brands Home and personal care - Sri-Lanka Consumer Brands - International Learning Segment
Slide 15: Consumer Brands
Consumer Brands Contribution to Group Sector Performance – 9M FY 2023-24 Revenue % 42% Key Highlights Revenue (LKR Mn) • A surge in demand was witnessed 13.2% across the industry driven by the 9M FY24 40% (YoY) festive season; however, it did not 9M FY23 15,135 15,433 reach the anticipated levels am
Slide 16: Home and Personal Care – Sri Lanka
Home and Personal Care – Sri Lanka 8 Key categories with market Purpose-driven brands touching the lives of the Sri Lankan consumer leading positions Extensions to the ‘Velvet’ and ‘Clogard’ Portfolio Inclusive Strong roots Parenting Stronger Make a Celebrating Enabling Both parents together Positiv
Slide 17: Home and Personal Care – International
Home and Personal Care – International Locally led and localised in Bangladesh Reach in Bangladesh 2 Geographies Bangladesh & West Bengal • All products are exclusively designed for Bangladesh. Rural penetration by • Extensive product portfolio with multiple value 19.3% Hemas Key categories 3 • Valu
Slide 18: Home and Personal Care – Sri Lanka and International
Home and Personal Care – Sri Lanka and International Sri Lanka International Revenue (LKR Mn) 12.0% Revenue Revenue (YoY) • Despite persistent inflation and the contraction in the 8,830 8,446 8,606 8,803 value-added hair oil (VAHO) market, ‘Kumarika’ • Prices were maintained in line with the market,
Slide 19: Learning Segment
Learning Segment Revenue 6 Key categories • ‘Atlas’ maintained its market-leading position in the mass market while simultaneously 60.0 % expanding market share in the newly entered Revenue (LKR Mn) premium and value-for-money segments. (YoY) High Efficiency and 8,000 7,666 productivity through lean
Slide 20: Healthcare Sector
Healthcare Sector Pharmaceutical Import, Marketing and Distribution Pharmaceutical Manufacturing Hospitals
Slide 21: Healthcare
Healthcare Contribution to Group Sector Performance – 9M FY 2023-24 Revenue % 56% Revenue (LKR Mn) 2.7% Key Highlights (YoY) 9M FY24 • Healthcare landscape continued to face 9M FY23 59% 17,639 17,912 challenges including persistent drug 18,000 16,712 16,000 15,757 15,326 shortages, unregulated impor
Slide 22: Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing
Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing Revenue • The Distribution vertical introduced over 20 new products during the Revenue (LKR Mn) quarter in critical spaces including oncology, gastroenterology and cardiology. • The Pharmaceutical Manufacturing Business
Slide 23: Hospitals
Hospitals Revenue 170+ Beds • A double-digit growth in surgical revenue and in-patient revenue under elevated occupancy levels. Revenue (LKR Mn) • Increased focus on anchor specialties including nephrology, cardiology gastroenterology and orthopedic segments continued to yield significant revenue gr
Slide 24: Mobility Sector
Mobility Sector Maritime Aviation
Slide 25: Mobility
Mobility Contribution to Group Sector Performance – 9M FY 2023-24 1% Revenue % Revenue (LKR Mn) Key Highlights 19.8% 9M FY24 2% • Amidst the recovery observed in (YoY) 9M FY23 500 460 merchandise exports towards the latter 418 384 376 months of the quarter, Port of Colombo 345 witnessed a 6.3 % grow
Slide 26: Living Our Purpose : New Initiatives
Living Our Purpose : New Initiatives INVESTING IN THE FUTURE CREATING A SAFER WORLD 75 STARTUPS In THREE Years “EMPOWER Launch of guide booklet focused on educating parents on prevention of FAMILIES TO home accidents ASPIRE FOR A BETTER ENCOURAGING RESPONSIBLE TOMORROW” RESPONSE TO ESCALATING PLASTI
Slide 27: Environmental and Social - Initiatives Impact
Environmental and Social - Initiatives Impact TACKLING MARINE POLLUTION PROVIDING WIGS TO CANCER PATIENTS CREATING A SAFER WORLD CREATING EQUAL LEARNING OPPURTUNITY 288,932+ KG 442 229 6,830 Plastic Collected Women Families Children, Teachers and Parents TACKLING PERIOD POVERTY TACKLING DIABETES CRE
Slide 28: Sustainability Performance – Q3 FY 24 vs Q3 FY23
Sustainability Performance – Q3 FY 24 vs Q3 FY23 Values of Fines for Non-Compliance Carbon Footprint (per Rs. Mn Revenue) 6.7% 1.4MT with Laws and Regulations in the NONE Social Economic Area Water Consumption 1.5 Total Work-Related Injury Rate 0.1 (per Rs. Mn Revenue) m3 (per 100 employee) Waste Re
Slide 29: Corporate Priorities
Focus on Personal care, Beauty and wellness Focus Areas with a drive for premiumiation and exploring underpenetrated Markets Corporate Priorities Strengthening value prepositions to grow market share Accelerating the M&A opportunities Accelerate exports and international expansion Consumer through O
Slide 30: Disclaimer
Disclaimer The material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this